Effect of Volume Guarantee-High Frequency Oscillatory Ventilation on Cerebral Blood Flow in Neonates

Sponsor
Ain Shams University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05592431
Collaborator
(none)
60
1
2
18.1
3.3

Study Details

Study Description

Brief Summary

A randomized controlled clinical trial evaluates cerebral blood flow changes associated with HFOV-VG in comparison to HFOV alone in preterm neonates with respiratory insufficiency during the period of invasive respiratory support

Condition or Disease Intervention/Treatment Phase
  • Device: High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)
  • Device: High Frequency Oscillatory Ventilation (SLE6000;SLE)
N/A

Detailed Description

Neonatal respiratory distress (NRD) is one of the most common problems in the first few days of neonatal life. NRD has been reported to be prevalent in 5 - 29% of the NICU hospitalized neonates.

High-frequency oscillatory ventilation (HFOV) has been used for more than three decades, it is a rescue maneuver for failed conventional mechanical ventilation. It delivers small tidal volumes to improve gas exchange. As it uses a low tidal volume, under the anatomical dead space at supra-physiological respiratory frequencies HFOV can reduce the risk of lung injury related to the ventilator and consequently reduce the risk of bronchopulmonary dysplasia HFOV is indicated for patients with neonatal air leak syndrome, persistent pulmonary hypertension, and meconium aspiration Several factors are known to influence cerebral perfusion during HFOV. Hypercapnia increases cerebral blood flow (CBF) while a reduction in PaCO2 leads to cerebral vasoconstriction and decreases CBF, Hypoxia is also known to increase CBF via cerebral vasodilation HFOV with volume guarantee (HFOV-VG) is a promising new ventilator mode for the treatment of respiratory failure in newborns. HFOV-VG is expected to result in less lung injury since it reduces fluctuations of high frequency tidal volume (VThf), reduces the number of out-of-target pCO2 values and provides fewer hypoxia attacks compared with HFOV alone

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Effect of Volume Guarantee-High Frequency Oscillatory Ventilation on Cerebral Blood Flow in Preterm Neonates
Anticipated Study Start Date :
Oct 27, 2022
Anticipated Primary Completion Date :
Nov 30, 2023
Anticipated Study Completion Date :
Apr 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: High Frequency Oscillatory Ventilation with Volume Guarantee (HFOV-VG )

After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV-VG ) will be assessed by doppler cerebral blood flow velocity measurements

Device: High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)
ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
Other Names:
  • transcranial Doppler ultrasonographic examination
  • Active Comparator: High Frequency Oscillatory Ventilation (HFOV)

    After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV) will be assessed by doppler cerebral blood flow velocity measurements

    Device: High Frequency Oscillatory Ventilation (SLE6000;SLE)
    ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
    Other Names:
  • transcranial Doppler ultrasonographic examination
  • Outcome Measures

    Primary Outcome Measures

    1. Doppler cerebral blood flow velocity measurements [72 hours]

      Investigate the effect of combining the VG mode with HFOV (HFOV-VG), versus the effect of HFOV alone, on Doppler cerebral blood flow velocity measurements

    Secondary Outcome Measures

    1. efficiency of HFOV-VG in comparison with HFOV alone [8 weeks or till patient discharged]

      Evaluate the efficiency of HFOV-VG in comparison with HFOV alone as a rescue therapy in providing adequate neonatal ventilation and its possible impact on the short-term clinical outcome in terms of mortality and morbidities of these preterm neonates.

    2. Duration of admission [8 weeks or till patient discharged]

      To document total number of days of admission

    3. Mortality rate [8 weeks or till patient death which comes first]

      To document incidence of mortality during hospitalization

    4. Incidence of feeding intolerance [8 weeks or till patient discharged]

      Percentage of Patients who developed feeding intolerance

    5. Days to reach full intake [8 weeks or till patient discharge which comes first]

      Number of days needed by each patient to reach full intake

    6. Chest x ray change [Before intubation and and after 2 hours on assigned mode]

      Chest x ray grading of RDS performed to patient before and after the assigned mode to compare lung aeration degree

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Day to 1 Month
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Preterm neonates with gestational age ≤ 35 weeks.

    2. Neonates with various causes of respiratory failure: respiratory distress syndrome (RDS), air leak syndromes, pneumonia, or pulmonary hemorrhage, failing with conventional ventilation (i.e. when conventional ventilation failed to maintain either oxygenation or ventilation) and are switched to HFOV as a rescue therapy.

    Exclusion Criteria:
    1. Preterm neonates with major upper or lower airway anomalies.

    2. Preterm neonates with significant congenital anomalies including cardiac, abdominal or respiratory

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Neonatal Intensive Care Units (NICUs), Ain Shams University Cairo Abbasia Egypt 11517

    Sponsors and Collaborators

    • Ain Shams University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mohamed Abdullah Moussa Akid, Assistant lecturer, Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT05592431
    Other Study ID Numbers:
    • MD 191/2022
    First Posted:
    Oct 24, 2022
    Last Update Posted:
    Oct 24, 2022
    Last Verified:
    Oct 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mohamed Abdullah Moussa Akid, Assistant lecturer, Ain Shams University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 24, 2022